Skip to main content
SpringerLink
Log in

Prävention des Benignen Prostatasyndroms

  • Chapter
  • First Online:
Benignes Prostatasyndrom

  • 364 Accesses

Zusammenfassung

Das benigne Prostatasyndrom (BPS) ist nicht nur in Deutschland, sondern auch in allen anderen westlichen Industrienationen die häufigste urologische Krankheit und die vierthäufigste sowie fünftteuerste Erkrankung bei Männern ≥50 Jahren. Basierend auf der Demografie und Prävalenzdaten des BPS in Deutschland sind hierzulande insgesamt etwa 2,5 Mio. Männer betroffen. Bei durchschnittlichen Kosten zur Diagnostik und Therapie von Männern mit BPS von ca. € 900 pro Patient und Jahr ist für das deutsche Gesundheitssystem ein jährlicher finanzieller Gesamtaufwand von ca. € 2,2 Mrd. für die Diagnostik und Therapie notwendig. Somit wären Gesundheitsprogramme zur Prävention des BPS sinnvoll.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Andersen JT, Nickel JC, Marshall VR et al (1997) Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 49:839–845

    Article  CAS  PubMed  Google Scholar 

  • Andriole GL, Bostwick DG, Brawley OW et al (2010) Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192–1202

    Article  CAS  PubMed  Google Scholar 

  • Badawy AA, Abdelhafez AA, Abuzeid AM (2012) Finasteride for treatment of refractory hemospermia: prospective placebo-controlled study. Int Urol Nephrol 44:371–375

    Article  CAS  PubMed  Google Scholar 

  • Berges R (2008) Epidemiologie des benignen Prostatasyndroms. Assoziierte Risiken und Versorgungsdaten bei deutschen Männern über 50. Urologe A 47:141–148

    Article  CAS  PubMed  Google Scholar 

  • Berges RR, Pientka L, Höfner K et al (2001) Male lower urinary tract symptoms and related health care seeking in Germany. Eur Urol 39:682–687

    Article  CAS  PubMed  Google Scholar 

  • Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48:398–405

    Article  CAS  PubMed  Google Scholar 

  • Cellek S, Rodrigo J, Lobos E et al (1999) Selective nitrergic neurodegeneration in diabetes mellitus – a nitric oxide-dependent phenomenon. Br J Pharmacol 128:1804–1812

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • D’Agate S, Wilson T, Adalig B et al (2020) Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH. World J Urol 38:463–472

    Article  PubMed  Google Scholar 

  • D’Agate S, Chavan C, Manyak M et al (2021) Impact of early vs. delayed initiation of dutasteride/tamsulosin combination therapy on the risk of acute urinary retention or BPH-related surgery in LUTS/BPH patients with moderate-to-severe symptoms at risk of disease progression. World J Urol. https://doi.org/10.1007/s00345-020-03517-0 (Ahead of print)

    Article  PubMed  Google Scholar 

  • Dahle SE, Chokkalingam AP, Gao YT et al (2002) Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol 168:599–604

    Article  CAS  PubMed  Google Scholar 

  • Dal Maso L, Zucchetto A, Tavani A et al (2006) Lifetime occupational and recreational physical activity and risk of benign prostatic hyperplasia. Int J Cancer 118:2632–2635

    Article  Google Scholar 

  • Di Silverio F, Gentile V, Pastore AL et al (2004) Benign prostatic hyperplasia: what about a campaign for prevention? Urol Int 72:179–188

    Article  PubMed  Google Scholar 

  • Durak I, Yilmaz E, Devrim E et al (2003) Consumption of aqueous garlic extract leads to significant improvement in patients with benign prostatic hyperplasia and prostate cancer. Nutr Res 23:199–204

    Article  CAS  Google Scholar 

  • Edinger MS, Koff WJ (2006) Effect of the consumption of tomato paste on plasma prostate-specific antigen levels in patients with benign prostatic hyperplasia. Braz J Med Biol Res 39:1115–1119

    Article  CAS  PubMed  Google Scholar 

  • ElJalby M, Thomas D, Elterma D, Chughtai B (2019) The effect of diet on BPH, LUTS and ED. World J Urol 37:1001–1005

    Article  PubMed  Google Scholar 

  • Gabrilove JL, Levine C, Kirschenbaum A, Droller M (1987) Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy. J Clin Endocrinol Metab 64:1331–1333

    Article  CAS  PubMed  Google Scholar 

  • Gacci M, Corona G, Vignozzi L et al (2015) Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int 115:24–31

    Article  PubMed  Google Scholar 

  • Golomb E, Rosenzweig N, Eilam R, Abramovici A (2000) Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 21:58–64

    CAS  PubMed  Google Scholar 

  • Gravas S, Oelke M (2010) Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. Word J Urol 28:9–15

    Article  CAS  Google Scholar 

  • Hong Y, Lee S, Won S (2019) The preventive effect of metformin on progression of benign prostatic hyperplasia: a nationwide population-based cohort study in Korea. PLoS ONE 14:e0219394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Issa MM, Fenter TC, Black L et al (2006) An assessment of the diagnosed prevalence of diseases in men 50 years or older. Am J Manag Care 12(4 Suppl.):S83–S89

    PubMed  Google Scholar 

  • Jakobsen SJ, Guess HA, Panser L et al (1993) A population-based study of health care-seeking behavior for treatment of urinary symptoms. The Olmsted County Study of Urinary Symptoms and Health Status among Men. Arch Fam Med 2:729–735

    Article  Google Scholar 

  • Kim HS, Bowen P, Chen L et al (2003) Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. Nutr Cancer 47:40–47

    Article  CAS  PubMed  Google Scholar 

  • Kristal AR, Arnold KB, Schenk JM et al (2007) Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. J Urol 177:1395–1400

    Article  PubMed  Google Scholar 

  • Kristal AR, Arnold KB, Schenk JM et al (2008) Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am J Epidemiol 167:925–934

    Article  PubMed  Google Scholar 

  • Lacey JV Jr, Deng J, Dosemeci M et al (2001) Prostate cancer, benign prostatic hyperplasia and physical activity in Shanghai China. Int J Epidemiol 30:341–349

    Article  PubMed  Google Scholar 

  • Marks LS, Roehrborn CG, Andriole GL (2006) Prevention of benign prostatic hyperplasia disease. J Urol 176:1299–1306

    Article  PubMed  Google Scholar 

  • McConnell JD, Roehrborn CG, Bautista OM et al (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398

    Article  CAS  PubMed  Google Scholar 

  • Mondul AM, Giovannucci E, Platz EA (2020) A prospective study of physical activity, sedentary behaviour, and incidence and progression of lower urinary tract symptoms. J Gen Intern Med 35:2281–2288

    Article  PubMed  PubMed Central  Google Scholar 

  • Moul S, McVary KT (2010) Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr Opin Urol 20:7–12

    Article  PubMed  Google Scholar 

  • Mühlstädt S, Oelke M (2019) Akuter Harnverhalt bei Männern: Die Wirksamkeit bei Alpha-Blockern beim Katheterauslassversuch nach Harnverhalt. Urologe A 58:680–685

    Article  PubMed  Google Scholar 

  • Narayan P, Evans CP, Moon T (2003) Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol 170:498–502

    Article  PubMed  Google Scholar 

  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421

    Article  Google Scholar 

  • Oelke M, Speakman M, Desgrandchamps F, Mamoulakis C (2015) Acute urinary retention rates in the general male population and in adult men with lower urinary tract symptoms participating in pharmacotherapy trials – a literature review. Urology 86:654–665

    Article  PubMed  Google Scholar 

  • Orsini N, RashidKhani B, Andersson SO et al (2006) Long-term physical activity and lower urinary tract symptoms in men. J Urol 176:2546–2550

    Article  PubMed  Google Scholar 

  • Park JS, Koo KC, Kim HK et al (2019) Impact of metabolic syndrome-related factors on the development of benign prostatic hyperplasia and lower urinary tract symptoms n Asian population. Medicine (Baltimore) 98:e17635

    Article  CAS  Google Scholar 

  • Parsons JK, Im R (2009) Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol 182:1463–1468

    Article  PubMed  Google Scholar 

  • Parsons JK, Carter HB, Partin AW et al (2006) Metabolic factors associated with benign prostatic hyperplasia. J Clin Endocrinol Metab 91:2562–2568

    Article  CAS  PubMed  Google Scholar 

  • Platz EA, Kawachi I, Rimm EB et al (1998) Physical activity and benign prostatic hyperplasia. Arch Intern Med 158:2349–2356

    Article  CAS  PubMed  Google Scholar 

  • Rahman NU, Phonsombat S, Bochinski D et al (2007) An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat. BJU Int 100:658–663

    Article  PubMed  Google Scholar 

  • Rastinehad AR, Ost MC, VanderBrink BA et al (2008) Persistent prostatic hematuria. Nat Clin Pract Urol 5:159–165

    Article  PubMed  Google Scholar 

  • Reich O, Gratzke C, Bachmann A et al (2008) Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. J Urol 180:246–249

    Article  PubMed  Google Scholar 

  • Roehrborn CG, Siami P, Barkin J et al (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT Study. Eur Urol 57:123–131

    Article  CAS  PubMed  Google Scholar 

  • Roehrborn CG, Nickel JC, Andriole GL et al (2011) Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by Dutasteride of Prostate Cancer Events (REDUCE) Trial. Urology 78:641–646

    Article  PubMed  Google Scholar 

  • Rohrmann S, Smit E, Giovannucci E, Platz EA (2004) Association between serum concentrations of micronutrients and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey. Urology 64:504–509

    Article  PubMed  Google Scholar 

  • Rohrmann S, Smit E, Giovannucci E, Platz EA (2005) Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 29:310–316

    Article  CAS  Google Scholar 

  • Rohrmann S, Giovannucci E, Willett WC, Platz EA (2007) Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr 85:523–529

    Article  CAS  PubMed  Google Scholar 

  • Swain J (1895) Castration for prostatic hypertrophy. Br Med J 1:12–13

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Takeuchi M, Masumori N, Tsukamoto T (2009) Contemporary patients with LUTS/BPH requiring prostatectomy have long-term history of treatment with alpha1-blockers and large prostates compared with past cases. Urology 74:606–609

    Article  PubMed  Google Scholar 

  • Tammela TL, Kontturi MJ (1995) Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. J Urol 154:1466–1469

    Article  CAS  PubMed  Google Scholar 

  • van Exel NJ, Koopmanschap MA, McDonnell J et al (2006) Medical consumption and costs during a one-year follow-up of patients with LUTS suggestive of BPH in six European countries: report of the TRIUMPH study. Eur Urol 49:92–102

    Article  PubMed  Google Scholar 

  • Vinarov AZ, Spivak LG, Platonova DV et al (2019) 15 years’ survey of safety and efficacy of Serenoa repens extract in benign prostatic hyperplasia patients with risk of progression. Urologia 86:17–22

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Kinderurologie und Urologische Onkologie, St. Antonius-Hospital, Gronau, Deutschland

    Matthias Oelke

Authors
  1. Matthias Oelke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Oelke .

Editor information

Editors and Affiliations

  1. Klinik für Urologie, Asklepios Klinik Barmbek, Hamburg, Hamburg, Deutschland

    Christopher Netsch

  2. Klinik für Urologie, Asklepios Klinik Barmbek, Hamburg, Hamburg, Deutschland

    Andreas J. Gross

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Oelke, M. (2022). Prävention des Benignen Prostatasyndroms. In: Netsch, C., Gross, A.J. (eds) Benignes Prostatasyndrom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-64334-1_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-64334-1_21

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-64333-4

  • Online ISBN: 978-3-662-64334-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation